Innovative diagnostics for a healthier world

CerMed’s Mission

Delivering Point of Care, diagnostic medical devices to world markets that:

• improve health outcomes and saving lives;
• provide access to effective, economic, quality solutions for low resource settings, and
• deliver significant value to partners and investors.

CerMed Markets

Disease Screening

CerMap™ and CerMark™, our Cervical Cancer Screening and HPV Detection products represent our company’s initial focus. These products are bringing low cost women’s health initiatives to underserved regions of the world, empowering women to take steps to reduce their risk of cervical cancer and HPV.

Cervical screening is typically undertaken by what is known as a Pap test processed in a laboratory. CerMed’s cervical screening system is a point-of-care approach, undertaken in minutes, for the replacement for such tests. There are approximately 160 million Pap smear procedures performed annually worldwide, which is estimated to be only 20% of the target population. This represents a market current market opportunity of $3-4 Million with market expansion growth to $20 Billion.

Other areas in future development include: other cancers (i.e., lung, prostate, ovarian, bladder, and colorectal) and infectious diseases (i.e., tuberculosis and pneumonia).

Women’s Controlled Contraception and HIV/AIDS Protection

CerCap™, a women’s controlled Combined Contraceptive/HIV Drug Delivery Device has the potential to change the future for disadvantaged women everywhere. This dual purpose, drug delivery product will provide protection, on a monthly basis, against unwanted pregnancy and reduce the risk of HIV infection. CerCap is presently in clinical trials in Africa. It will be provided to developing markets through organizations such as PATH, Planned Parenthood, WHO, UN and others. This technology can be leveraged in the development of additional dual purpose drug delivery devices for other sexually transmitted diseases.

There are currently 34 million people living with HIV/AIDS with 2.5 million new cases per year, over 50% of these being women. This represents a current market opportunity of $13 Billion with market expansion growth to $52 Billion.